# OnCo record cardiff-oncology (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/cardiff-oncology/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "cardiff-oncology" ;
  schema:name "Cardiff Oncology"@en ;
  schema:alternateName "Trovagene"@en, "Cardiff Oncology, Inc."@en, "NASDAQ:CRDF"@en ;
  schema:description "Cardiff Oncology is a San Diego biotech developing onvansertib, an oral PLK1 inhibitor that is being tested with chemotherapy and bevacizumab as first-line treatment for RAS-mutant colorectal cancer."@en ;
  schema:url <https://onco.cc/companies/cardiff-oncology/>, <https://www.cardiffoncology.com/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://www.cardiffoncology.com/> ;
  onco:tag "drug-maker" ;
  schema:addressCountry "US" ;
  onco:drugs <https://onco.cc/drugs/onvansertib/> .